



PATENT APPLICATION  
CH 7904  
LeA 36,181

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN APPLICATION OF )  
BENJAMIN MESEQUER ET AL )  
SERIAL NO.: 10/643,552 )  
FILED: AUGUST 19, 2003 )  
TITLE: CHIRAL DIPHOSPHORUS )  
COMPOUNDS AND THEIR )  
TRANSITION METAL COMPLEXES )

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This disclosure statement under 37 CFR 1.97 & 1.98 is submitted before the first Office Action in order that the Patent and Trademark Office may consider the relevancy of certain information to the invention described and claimed in the subject application, and in compliance with the regulations concerning information disclosure statements. Enclosed are copies of the following:

- a) the Search Report received in the corresponding application pending in the European Patent Office ; and an English language translation thereof; and

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, Alexandria, VA 22313-1450, on the date below.

Godfried R. Akorfi Reg. No. 28/779

Name of applicant, assignee or Registered Representative


Signature

March 5, 2004  
Date

- b) the documents cited by the European Patent Office in the Search Report (except the documents previously submitted) listed on the attached Form PTO-1449; and
- c) the documents cited by the European Patent Office in the Search Report and a corresponding English language equivalent OR English Abstract (except for documents previously submitted) listed on the attached Form PTO 1449.


This Information Disclosure Statement should not be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, that any reference mentioned herein constitutes prior art, or that the references listed, severally or in any combination with one another or with any other information, are believed to render any claim in the subject application prima facie unpatentable.

Respectfully submitted,

By   
Godfried R. Akorli  
Attorney for Applicants  
Reg. No. 28,779

Bayer Chemicals Corporation  
100 Bayer Road  
Pittsburgh, Pennsylvania 15205-9741  
(412) 777-3061  
FACSIMILE PHONE NUMBER:  
(412) 777-2612

F:\SHARED\JD\GRA\gra156 7335 INFORM B EPO.doc



Form PTO 1449 Rev. 7-80	U.S. Department of Commerce Patent and Trademark Office <b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use Several Sheets If Necessary)	Atty. Docket No. Ch 7904/LeA 36,181	Serial No. 10/643,552
		Applicant Benjamin Mesequer et al	
		Filing Date 8/19/2003	Group To be assigned

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,484,926	01/16/96	Dressman et al.	546	114	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							Yes	No*
	AL	91201	02/24/1897	Germany				x
	AM	0639559	02/22/95	Europe				
	AN							
	AO							
	AP							

**OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER Initial if references considered, whether or not citation is in conformance with MPEP 609: Draw line through if not in conformance and not considered. Include copy of this form with next communication to applicant.

- Neither English Language Equivalent nor an English Language Translation is available.

F:\SHARED\WD\GRA\7335 pto 1449.doc